3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Tumor Lysis Syndrome
1
Lymphoma
1
Leukemia
1
Inflammation
1
Hyperuricemia
1
Gout
1
Cardiovascular Diseases
1
Arthritis
1
Interventions
Cyclophosphamide
227
Cytarabine
194
fludarabine phosphate
138
Methotrexate
132
Filgrastim
127
Busulfan
103
Etoposide
99
Peripheral Blood Stem Cell Transplantation
91
Rituximab
81
fludarabine
77
Radiotherapy
77
Vincristine
74
Daunorubicin
68
Antilymphocyte Serum
65
Cyclosporine
63
Dexamethasone
61
Tacrolimus
56
Mycophenolic Acid
53
Melphalan
52
Imatinib Mesylate
50
Granulocyte Colony-Stimulating Factor
50
Mercaptopurine
46
Whole-Body Irradiation
45
Idarubicin
43
sargramostim
42
Methylprednisolone
42
Doxorubicin
41
Flow Cytometry
40
Prednisone
39
Clofarabine
39
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia
×
Febuxostat
×
Clear all
NCT01724528
2014-11-03
FLORENCE
Menarini Group
Phase 3
Completed
346 enrolled
16 charts